Rolston K, Ho D H, LeBlanc B, Bodey G P
Department of Medical Specialties, University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston.
Chemotherapy. 1988;34(6):448-54. doi: 10.1159/000238607.
The in vitro activity of Fleroxacin (Ro23-6240; AM 833), a new fluorinated 4-quinolone, was compared to that of ciprofloxacin, enoxacin and A-56620, against 747 isolates from cancer patients. Fleroxacin inhibited more than 90% of Enterobacteriacea isolates at a concentration of less than or equal to 0.25 micrograms/ml. It was also extremely active against Aeromonas hydrophila and Haemophilus influenzae isolates with MIC90 values of 0.12 and 0.06 micrograms/ml, respectively. The MIC90 for Acinetobacter spp. was 1.0 micrograms/ml, for Pseudomonas aeruginosa and Pseudomonas fluorescens 4.0 micrograms/ml, and for other Pseudomonas spp., 8.0 micrograms/ml. Staphylococcus aureus isolates including methicillin-resistant strains were inhibited by less than or equal to 1.0 microgram/ml. The MIC90 for three different species of coagulase-negative Staphylococci was 1.0 microgram/ml. Streptococcal species required 8-16 micrograms/ml for inhibition. Fleroxacin was also active against group JK-diphtheroids and Bacillus cereus. The overall activity of fleroxacin was similar to that of enoxacin and less than that of A-56620 and ciprofloxacin.
将新型氟化4-喹诺酮类药物氟罗沙星（Ro23 - 6240；AM 833）的体外活性与环丙沙星、依诺沙星和A - 56620进行比较，以检测其对747株癌症患者分离菌株的活性。氟罗沙星在浓度小于或等于0.25微克/毫升时可抑制90%以上的肠杆菌科分离菌株。它对嗜水气单胞菌和流感嗜血杆菌分离菌株也具有极高活性，其MIC90值分别为0.12和0.06微克/毫升。不动杆菌属的MIC90为1.0微克/毫升，铜绿假单胞菌和荧光假单胞菌为4.0微克/毫升，其他假单胞菌属为8.0微克/毫升。包括耐甲氧西林菌株在内的金黄色葡萄球菌分离菌株在浓度小于或等于1.0微克/毫升时受到抑制。三种不同的凝固酶阴性葡萄球菌的MIC90为1.0微克/毫升。链球菌属菌株抑制浓度需要8 - 16微克/毫升。氟罗沙星对JK组类白喉杆菌和蜡样芽孢杆菌也有活性。氟罗沙星的总体活性与依诺沙星相似，低于A - 56620和环丙沙星。
